4.7 Article

Obesity-Dependent Adipokine Chemerin Suppresses Fatty Acid Oxidation to Confer Ferroptosis Resistance

Journal

CANCER DISCOVERY
Volume 11, Issue 8, Pages 2072-2093

Publisher

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/2159-8290.CD-20-1453

Keywords

-

Categories

Funding

  1. National Institutes of Health [R01CA254409, P30CA240139, R01DK120679, P50AA024333, P01HL147823, U24DK097209]

Ask authors/readers for more resources

The study found that obesity and tumor cells contribute to ccRCC through the expression of chemerin, which plays an indispensable role in ccRCC biology. Inhibition of chemerin can reduce lipid accumulation and inhibit tumor growth, highlighting potential therapeutic strategies for patients with ccRCC. Targeting lipid metabolism via inhibition of a soluble factor like chemerin presents a promising pharmacologic approach.
Clear cell renal cell carcinoma (ccRCC) is characterized by accumulation of neutral lipids and adipogenic transdifferentiation. We assessed adipokine expression in ccRCC and found that tumor tissues and patient plasma exhibit obesity-dependent elevations of the adipokine chemerin. Attenuation of chemerin by several approaches led to significant reduction in lipid deposition and impairment of tumor cell growth in vitro and in vivo. A multi-omics approach revealed that chemerin suppresses fatty acid oxidation, preventing ferroptosis, and maintains fatty acid levels that activate hypoxia-inducible factor 2 alpha expression. The lipid coenzyme Q and mitochondrial complex IV, whose biogeneses are lipid-dependent, were found to be decreased after chemerin inhibition, contributing to lipid reactive oxygen species production. Monoclonal antibody targeting chemerin led to reduced lipid storage and diminished tumor growth, demonstrating translational potential of chemerin inhibition. Collectively, the results suggest that obesity and tumor cells contribute to ccRCC through the expression of chemerin, which is indispensable in ccRCC biology. SIGNIFICANCE: Identification of a hypoxia-inducible factor-dependent adipokine that prevents fatty acid oxidation and causes escape from ferroptosis highlights a critical metabolic dependency unique in the clear cell subtype of kidney cancer. Targeting lipid metabolism via inhibition of a soluble factor is a promising pharmacologic approach to expand therapeutic strategies for patients with ccRCC.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available